The FDA’s Role in the Development of Bioterrorist Countermeasures

DSpace/Manakin Repository

The FDA’s Role in the Development of Bioterrorist Countermeasures

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Guerra, Marcelo en_US
dc.date.accessioned 2012-12-07T15:17:15Z
dc.date.issued 2004 en_US
dc.identifier.citation The FDA’s Role in the Development of Bioterrorist Countermeasures (2004 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:10015278
dc.description.abstract As the agency that approves drug products used to treat bioterrorist diseases, the FDA plays a significant role in the domestic preparation against a bioterrorist attack. The changes that occurred at the agency in response the AIDS and cancer crises of the 1980’s have served as a blueprint for the changes made in response to the terrorist threat. These changes, often desirable but sometimes not, push even further the agency’s role as a collaborator in drug development. The paper investigates the threat of a biological weapon attack and the changes to the drug approval process that this threat has prompted. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject bioterrorism en
dc.title The FDA’s Role in the Development of Bioterrorist Countermeasures en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-12-07T15:17:15Z

Files in this item

Files Size Format View
Guerro.pdf 301.9Kb PDF View/Open
Guerro.rtf 295.6Kb RTF file View/Open
Guerro.html 209.0Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters